Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284670 | 1.00 | SLC7A5 (0.60) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL13108107 | 1.00 | SLC7A5 (0.60) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL11237591 | 0.91 | TBXAS1 (0.59) | SLC7A5ESR1TBXAS1PTGS1PTGS2 | |
| SCHEMBL14640275 | 0.89 | FFAR1 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL19553694 | 0.85 | PTGS1 (0.66) | ESR1TBXAS1PTGS1PTGS2LMNA | |
| SCHEMBL7753247 | 0.85 | TAAR1 (0.57) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL17083020 | 0.85 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL15236840 | 0.85 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL12229428 | 0.83 | ESR1 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL12696346 | 0.83 | TBXAS1 (0.53) | ESR1TBXAS1PTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023191951-A1 | SMALL MOLECULE ALLOSTERIC MODULATORS OF THE SEROTONIN (5-HT) 5-HT2C AND 5-HT2A RECEPTORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2021-10-21 | — | — | US | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20120100579-A1 | TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER | TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7619116-B2 | Intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | Products Chimiques Auxiliaires Et de Synthese (FR) | 2009-11-17 | — | — | US | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7282606-B2 | Process for preparation of tamsulosin and its aralkylamine derivatives | WELL-BEING BIOCHEMICAL CORP. (TW) | 2007-10-16 | — | — | US | disclosed |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070015939-A1 | Process for preparation of tamsulosin and its aralkylamine derivatives | WELL-BEING BIOCHEMICAL CORP (TW) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, TIMP3 | SLC7A5 2427/4885TAAR1 4238/4885SLC6A2 587/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | SLC7A5 2661/4885TAAR1 4199/4885SLC6A2 993/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | SLC7A5 3348/4885TAAR1 3268/4885SLC6A2 4036/4885 |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | SLC7A5 1121/4885TAAR1 1873/4885SLC6A2 3415/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | SLC7A5 1061/4885TAAR1 2680/4885SLC6A2 317/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SLC7A5 1955/4885TAAR1 4220/4885SLC6A2 4290/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | SLC7A5 1597/4885TAAR1 4276/4885SLC6A2 4347/4885 |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | SLC7A5 4139/4885TAAR1 4428/4885SLC6A2 4834/4885 |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | ADRB1, AVPR2, ADRA1A | SLC7A5 890/4885TAAR1 111/4885SLC6A2 516/4885 |
| US-20070015939-A1 | Process for preparation of tamsulosin and its aralkylamine derivatives | ADRB1, ADRA2B, ADRA2A | SLC7A5 2864/4885TAAR1 114/4885SLC6A2 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.